Tools · Private company
Oryzon Genomics S.A.
Track this companyFree. Adds Oryzon Genomics S.A. to your Dealase workspace and tells you when its record changes.
Clinical trials63 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- ORY-2001 High dosePhase 2 · Mild to Moderate Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ORY-2001 Low dosePhase 2 · Mild to Moderate Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- vafidemstatPhase 2 · Borderline Personality DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Gilteritinib Oral TabletPhase 1 · Acute Myeloid Leukemia, in RelapseClinicalTrials.gov · fetched Nov 12, 2026
- IadademstatPhase 1 · Acute Myeloid Leukemia, in RelapseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Iadademstat + SBRT With Atezo in ES-SCLCPHASE1 · RECRUITING · started Jan 20, 2026ClinicalTrials.gov NCT07113691 · fetched Nov 12, 2026
- Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid LeukemiaPHASE1 · RECRUITING · started Aug 22, 2024ClinicalTrials.gov NCT06357182 · fetched Nov 12, 2026
- Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NETPHASE2 · TERMINATED · started Dec 21, 2022ClinicalTrials.gov NCT05420636 · fetched Nov 12, 2026
- Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)PHASE1 · ACTIVE_NOT_RECRUITING · started Nov 14, 2022ClinicalTrials.gov NCT05546580 · fetched Nov 12, 2026
- Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder PopulationPHASE2 · COMPLETED · started Mar 26, 2021ClinicalTrials.gov NCT04932291 · fetched Nov 12, 2026
- Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's DiseasePHASE2 · COMPLETED · started May 16, 2019ClinicalTrials.gov NCT03867253 · fetched Nov 12, 2026